Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
复制标题
DOI：
10.1186/s12931-019-1021-2
复制
发表时间：
2019-03-12
影响因子：
5.8
通讯作者：
Noble, Paul W.
中科院分区：
文献类型：
--
作者：
Costabel, Ulrich;Albera, Carlo;Noble, Paul W.
来自晚期特发性肺纤维化（IPF）患者的对照临床研究数据可以为临床实践提供信息，但它们是有限的，因为这一亚群通常被排除在临床试验之外。这些开放标签长期扩展研究RECAP （NCT00662038）的探索性事后分析旨在评估吡非尼酮在晚期IPF患者中的有效性和安全性。根据基线时肺功能损害的程度对患者进行分类：更晚期（百分比预测FVC）
Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extension study RECAP (NCT00662038) aimed to assess the efficacy and safety of pirfenidone in patients with more advanced IPF. Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC